Exchange: NASDAQ·Updated 04:10 PM EDT
News
all
press releases
Seaport Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress
Seaport Therapeutics, Inc., (Nasdaq: SPTX) (Seaport or the Company), a clinical-stage therapeutics company that is inventing and developing novel neuropsychiatric medicines, today announced financial results for the second quarter of 2026 and highlighted recent corporate and clinical progress. The...
Business Wire
More News
PureTech Founded Entity Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo in Healthy Volunteers
PureTech Health plc (LSE: PRTC) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, notes that its Founded Entity, Seaport Therapeutics, announced positive data from the multiple-ascending dose (MAD...
Business Wire
Seaport Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress
Seaport Therapeutics, Inc., (Nasdaq: SPTX) (Seaport or the Company), a clinical-stage therapeutics company that is inventing and developing novel neuropsychiatric medicines, today announced financial results for the first quarter of 2026 and highlighted recent corporate and clinical progress. The...
Business Wire
Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo in Healthy Volunteers
Seaport Therapeutics, Inc., (Nasdaq: SPTX) (Seaport or the Company), a clinical-stage therapeutics company that is inventing and developing novel neuropsychiatric medicines, today announced positive data from the multiple-ascending dose (MAD) portion of its Phase 1 proof-of-concept clinical trial...
Business Wire
Seaport Therapeutics to Participate in Two Upcoming Investor Conferences
Seaport Therapeutics, Inc., (Nasdaq: SPTX) (Seaport or the Company), a clinical-stage therapeutics company that is inventing and developing novel neuropsychiatric medicines, today announced that members of its management team will participate in the following upcoming investor conferences: Goldman...
Business Wire
Seaport Therapeutics Announces Pricing of Upsized Initial Public Offering
Seaport Therapeutics, Inc., (Nasdaq: SPTX) (Seaport or the Company), a clinical-stage therapeutics company that is inventing and developing neuropsychiatric medicines, today announced the pricing of...
Business Wire

Advertisement|Remove ads.